# Read the source with the claim beside it Here are the sources behind the linked statements. The notes say what each adds, so you can open the document that answers your question. ## Match the source to the question A medicine label gives its uses and warnings. A trial tells us what happened to a particular group. A review brings research together, but cannot fill in studies that haven’t been done. When a finding sounds broad, look for who took part, what was compared and what changed. Those details tell us how far the result can travel. A result about a cream, for instance, cannot answer a question about an injection. For regulatory wording, dates matter too. [Body and treatment](/body-and-treatment) explains why a withdrawn nomination isn’t an approval. These links are for understanding the claims here; they don’t replace a personal medical assessment. ## Medicine labels and human trials ### [Semaglutide prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) The medicine’s actions and warnings, including the boxed thyroid warning. DailyMed, US National Library of Medicine ### [Semaglutide in adults with overweight or obesity](https://pubmed.ncbi.nlm.nih.gov/33567185/) Weight-management research with a placebo comparison and lifestyle support. New England Journal of Medicine, 2021 ### [Tirzepatide prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) Stomach problems, the thyroid warning and the birth control interaction. DailyMed, US National Library of Medicine ### [Tirzepatide in adults with obesity or overweight](https://pubmed.ncbi.nlm.nih.gov/35658024/) Weight-management research in adults without diabetes, with a placebo comparison. New England Journal of Medicine, 2022 ### [Bremelanotide prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) The narrow approved use, blood-pressure warning and cardiovascular restrictions. DailyMed, US National Library of Medicine ## Research with open questions ### [FDA’s assessment of BPC-157 evidence](https://www.fda.gov/media/193343/download) Small human studies, missing comparisons and unanswered safety questions. US FDA, July 2026 ### [GHK biology and the reasons for research interest](https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/) Background biology; it does not establish benefits from an injection. BioMed Research International, 2015 ### [A review of topical GHK research](https://pubmed.ncbi.nlm.nih.gov/39963574/) The shortage of studies in people using products applied to skin. Bioimpacts, 2025 ### [The notice withdrawing the former sermorelin approvals](https://www.federalregister.gov/documents/2009/05/19/E9-11628/novartis-pharmaceuticals-corp-et-al-withdrawal-of-approval-of-92-new-drug-applications-and-49) The record ending the former approvals; read with the later finding. Federal Register, 2009 ### [FDA’s later determination about former sermorelin medicines](https://www.federalregister.gov/d/2013-04827) The later finding does not restore the withdrawn approvals. Federal Register, 2013 ### [A small study of hormone release in older men](https://pubmed.ncbi.nlm.nih.gov/9005976/) A hormone rise without a change in body fat or muscle. Metabolism, 1997 ### [A review of sermorelin’s former specialist uses](https://pubmed.ncbi.nlm.nih.gov/18031173/) Older safety observations, mostly from specialist studies involving children. BioDrugs, 1999 ### [NAD+ and cell metabolism](https://pubmed.ncbi.nlm.nih.gov/20007326/) How NAD+ works in cells, rather than evidence for infusions. Endocrine Reviews, 2010 ### [Human evidence on NAD+ precursors and ageing](https://pubmed.ncbi.nlm.nih.gov/41083806/) Blood readings do not establish health benefits; human evidence remains limited. Nature Metabolism, 2025 ### [A small retrospective report on infusion tolerability](https://pubmed.ncbi.nlm.nih.gov/41704678/) Symptoms reported in one setting, without a reliable rate for everyone. Frontiers in Aging, 2026 ## The route to legitimate care ### [FDA’s explanation of compounding](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) Why some patients need a medicine made for them. US FDA ### [FDA on the risks of compounded medicines](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs) What FDA has not reviewed before these medicines are marketed. US FDA ### [FDA’s peptide safety concerns and withdrawn nominations](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) Withdrawn nominations still carry safety concerns, without individual withdrawal dates. US FDA ### [HHS on permission to practise across state lines](https://telehealth.hhs.gov/licensure/getting-started-licensure) How the patient’s location affects permission to practise online. US Department of Health and Human Services ### [State medical boards and public licence records](https://www.fsmb.org/u.s.-medical-regulatory-trends-and-actions/guide-to-medical-regulation-in-the-united-states/information-for-consumers/) Public licence and discipline records, with no guarantee of judgement. Federation of State Medical Boards Leave some space for whatever you wonder about next. [Return to the reading syllabus](/) --- [Skip to reading](/references#reading) [Peak Health Peptides](/) [Words for everyday life](/peptide-words) Give the words you keep hearing a useful meaning. [Medicines and research](/body-and-treatment) See why a body’s peptide and a treatment differ. [A question for care](/care-conversation) Take a clearer evidence question to a clinician. We keep this a reading guide: explanations to take away, with no clinical care, dispensing or sales. [References](/references) · [About](/about) · [Contact](/contact) © 2026 Peak Health Peptides